Checkmate 227 & Keynote 042 Potential Practice Changing Approaches

Checkmate 227 & Keynote 042 Potential Practice Changing Approaches

moasc

8 months
395 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA, Director Of Signal Transduction And Therapeutics, Jonsson Comprehensive Cancer Center At UCLA, Discusses Checkmate 227 & Keynote 042 Potential Practice Changing Approaches. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org...
Up Next Autoplay
Determination from the FDA
Determination from the FDA
Category: Prostate Cancer
6 Views
moasc 2 months
The Role of Nephrectomy
The Role of Nephrectomy
Category: Kidney Cancer
3 Views
moasc 2 months
ENZAMET and TITAN Study
ENZAMET and TITAN Study
Category: Acute Lymphoblastic Leukemia
14 Views
moasc 2 months
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
11 Views
moasc 2 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
10 Views
moasc 2 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
3 Views
moasc 2 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
6 Views
moasc 2 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
2 Views
moasc 2 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
1 Views
moasc 2 months
IMNC Data
IMNC Data
Category: Melanoma and Skin Cancer
4 Views
moasc 2 months